Marshall Wace North America’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Marshall Wace North America’s Portfolio LJPC Stock Details LJPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-375,046	Closed	-$2.41M	–	1894
2019 Q1	$2.41M	Buy	375,046 +373,504	+24,222%	+$2.43M	0.02%	456
2018 Q4	$15K	Buy	+1,542	New	+$23.2K	﹤0.01%	1407
2018 Q1	–	Sell	-55,852	Closed	-$1.8M	–	1899
2017 Q4	$1.8M	Buy	+55,852	New	+$1.83M	0.01%	861
2017 Q2	–	Sell	-19,796	Closed	-$594K	–	1580
2017 Q1	$594K	Buy	+19,796	New	+$505K	﹤0.01%	792

Other funds holding LJPC

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's LJPC Position: Q2 2019 in Review

Marshall Wace North America sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2019, closing a stake of 375,046 shares — an estimated $2.41M sold.

Marshall Wace North America first reported a position in LJPC in Q1 2017 and held it in 4 quarters. The position peaked at $2.41M in Q1 2019. 80 funds tracked by Wall St. Rank hold LJPC as of Q2 2019.

Marshall Wace North America reported no remaining La Jolla Pharmaceutical Company position as of Q2 2019 after selling out during the quarter.
Marshall Wace North America sold 375,046 La Jolla Pharmaceutical Company shares in Q2 2019, an estimated $2.41M.
Marshall Wace North America first reported a position in La Jolla Pharmaceutical Company in Q1 2017 and held it in 4 quarters.
Marshall Wace North America's La Jolla Pharmaceutical Company position peaked at $2.41M in Q1 2019.
80 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.